The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes

      This CME activity is supported by an educational grant from GlaxoSmithKline, Research Triangle Park, North Carolina.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davies M.J.
        • Woolf N.
        • Robertson W.B.
        Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi.
        Brit Heart J. 1976; 38: 659-664
        • De Wood M.A.
        • Spores J.
        • Notske R.
        • Mouser L.T.
        • Burroughs R.
        • Golden M.S.
        • Lang H.T.
        Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.
        N Engl J Med. 1980; 303: 897-902
        • Fuster V.
        • Badimon L.
        • Badimon J.J.
        • Chesebro J.H.
        The pathogenesis of coronary artery disease and the acute coronary syndromes.
        N Engl J Med. 1992; 326 (;310–318): 242-250
        • Fulton R.M.
        • Duckett K.
        Plasma-fibrinogen and thromboemboli after myocardial infarction.
        Lancet. 1976; 2: 1161-1164
        • Thomas A.C.
        • Knapman A.
        • Kirkler D.M.
        • Davies M.J.
        Community study of the causes of “natural” sudden death.
        BMJ. 1988; 297: 1453-1456
        • FRISC Study Group
        Low-molecular-weight heparin during instability in coronary artery disease.
        Lancet. 1996; 347: 561-568
        • The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
        Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
        N Engl J Med. 2006; 354: 1464-1476
        • The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
        Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
        JAMA. 2006; 295: 1519-1530
        • Turpie A.G.G.
        • Bauer K.A.
        • Eriksson B.I.
        • Lassen M.R.
        • Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery
        A meta-analysis of 4 randomized double blind studies.
        Arch Intern Med. 2003; 62: 1833-1840
        • Buller H.R.
        • Davidson B.L.
        • Decousus H.
        • Gallus A.
        • Gent M.
        • Piovella F.
        • Prins M.H.
        • Raskob G.
        • Segers A.E.M.
        • Cariou R.
        • et al.
        Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
        Ann Intern Med. 2004; 140: 867-873
        • The Matisse Investigators
        Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
        N Engl J Med. 2003; 349 (; erratum, N Engl J Med 2004;350:423): 1695-1702
        • The Oasis-6 Trial Group
        Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction.
        JAMA. 2006; 295: 1519-1530
        • Stone G.W.
        • McLaurin B.T.
        • Cox D.A.
        • Bertrand M.E.
        • Lincoff A.M.
        • Moses J.W.
        • White H.D.
        • Pocock S.J.
        • Ware J.H.
        • Feit F.
        • et al.
        • ACUITY Investigators
        Bivalirudin for patients with acute coronary syndromes.
        N Engl J Med. 2006; 355: 2203-2216
        • Antman E.M.
        • Morrow D.A.
        • McCabe C.H.
        • Murphy S.A.
        • Ruda M.
        • Sadowski Z.
        • Budaj A.
        • López-Sendón J.L.
        • Guneri S.
        • Jiang F.
        • et al.
        • ExTRACT-TIMI 25 Investigators
        Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
        N Engl J Med. 2006; 354: 1477-1488
        • Schühlen H.
        • Hadamitzky M.
        • Walter H.
        • Ulm K.
        • Schömig A.
        Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial.
        Circulation. 1997; 95: 2015-2021
        • Singh K.P.
        • Roe M.T.
        • Peterson E.D.
        • Chen A.Y.
        • Mahaffey K.W.
        • Goodman S.G.
        • Harrington R.A.
        • Smith Jr, S.C.
        • Gibler W.B.
        • Ohman E.M.
        • Pollack Jr, C.V.
        • CRUSADE Investigators
        Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
        J Thromb Thrombolysis. 2006; 21: 211-220
        • American Heart Association Statistics Committee and Stroke Statistics Committee
        Heart disease and stroke statistics—2007 update.
        Circulation. 2007; 115: e69-e171